Bioreductive drugs for cancer therapy: The search for tumor specificity

International Journal of Radiation Oncology, Biology, Physics

Volumn 29, Issue 2, 1994, Pages 231-238

  Adams, Gerald E ^a   Stratford, Ian J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

31P magnetic resonance spectroscopy (MRS); Bioreductive drugs; DT diaphorase; Hypoxia; Photodynamic therapy (PDT)

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ARGININE DERIVATIVE; CYTOTOXIC AGENT; HETEROCYCLIC NITRO COMPOUND; HYDRALAZINE; IMIDAZOLE DERIVATIVE; INTERLEUKIN 2; MISONIDAZOLE; MITOFLAXONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDE; PD 144871; PHOTOFRIN; PHTHALOCYANINE ALUMINUM; PORFIROMYCIN; QUINONE DERIVATIVE; RB 90740; RB 92042 X; RB 92043 X; TIRAPAZAMINE; TUCARESOL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASOACTIVE AGENT; VELARESOL;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG STRUCTURE; ENANTIOMER; ENZYME ACTIVITY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; HUMAN; HYPOXIA; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR CELL; VOMITING;

ANIMAL; ANTINEOPLASTIC AGENTS; HUMAN; NEOPLASMS; NITRIC OXIDE; NITROIMIDAZOLES; OXIDATION-REDUCTION; PHOTOCHEMOTHERAPY; PORFIROMYCIN; PRODRUGS; TRIAZINES;

EID: 0028339820     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(94)90267-4     Document Type: Article

References (34)

1. Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin-implications for therapy
2. 31P magnetic resonance spectroscopy measurements of changes in experimental tumour metabolism be related to modification of oxygenation status?
3. Induction of severe tumor hypoxia by modifiers of the oxygen affinity of hemoglobin
4. Interleukin-la induced tumour vascular pathophysiologics can be exploited with bioreductive alkylating agents
5. Assessing the bioreductive effectiveness of the nitroimidazole RSU 1069 and its prodrug RB6145: With particular reference to in vivo methods of evaluation
6. Increasing the effect of photodynamic therapy on the RIF-1 tumour using the bioreductive drugs RSU 1069 and RB 6145
7. 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification
8. Bioreductive drugs can enhance the anti-tumour effect of photodynamic therapy
9. Potentiation of RSU 1069 tumour cytotoxicity by hydralazine: a new approach to selective therapy
10. Hydralazine-induced tumor hypoxia: A potential target for cancer chemotherapy
11. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU 1069
12. Dual function 2-nitroimidazoles and hypoxic cell radiosensitizers and bioreductive cytotoxins: In vivo evaluation in KHT murine sarcomas
13. Oral (p.o.) dosing with RS 1069 or RB6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (IP) administration in mice
14. High levels of expression of the ENCES NAD(P)H:(quinone acceptor) oxidoreductase (NQO 1) gene in tumour cells compared to normal cells of the same origin
15. Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid
16. Induction of tumour hypoxia by FAA and TNF: Interaction with bioreductive drugs
17. Treatment of Dunning R3327-AT rat prostate tumours with photodynamic therapy in com bination with misonidazole
18. Effects of hypoxia and reoxygenation on the conversion of xanthine dehydrogenase to oxidase in Chinese hamster V79 cells
19. Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic and not hypoxic conditions
20. Synthesis and evaluation of .alpha.-[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of .alpha.-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogs which are radiosensitizers and bioreductively activated cytotoxins
21. Secondgeneration 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumour agents; Pharmacology and activity in vitro and in vivo
22. Nitric oxide; Physiology, pathophysiology and pharmacology
23. The identification of heme oxygenase as a major hypoxic stress protein in Chinese hamster ovary cells
24. Effects of hypoxia upon detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells (Abst. 68)
25. The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase?
26. Cytosolic NAD(P)H:(quinone acceptor) oxide reductase in human normal and tumour tissue. Effects of cigarette smoking and alcohol
27. The use of DTdiaphorase for the detection of foci of early neoplastic transformation in rat liver
28. Rationale for selection of PD 144872, the Risomer of RB6145, for clinical development as a radiosensitizer (Abst. 2155)
29. Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability
30. Structureactivity relationships for benzotriazene-di-N-oxides
31. SR 4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells